Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) have been given a consensus rating of “Moderate Buy” by the ten brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $190.22.
KRYS has been the subject of a number of research reports. Evercore ISI increased their target price on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Citigroup reissued a “neutral” rating and issued a $204.00 target price (up previously from $195.00) on shares of Krystal Biotech in a research report on Tuesday, August 6th. Chardan Capital upped their price target on Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Finally, HC Wainwright lifted their price objective on shares of Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a report on Wednesday.
Check Out Our Latest Stock Report on Krystal Biotech
Insider Buying and Selling at Krystal Biotech
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. Scout Investments Inc. acquired a new stake in Krystal Biotech during the 1st quarter valued at $8,976,000. Fiera Capital Corp acquired a new stake in shares of Krystal Biotech during the 4th quarter worth about $1,973,000. Sei Investments Co. grew its stake in Krystal Biotech by 128.3% in the 1st quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock valued at $6,005,000 after buying an additional 18,968 shares during the last quarter. Vanguard Group Inc. raised its holdings in Krystal Biotech by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after acquiring an additional 35,632 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new stake in Krystal Biotech during the first quarter worth approximately $3,175,000. 86.29% of the stock is currently owned by institutional investors.
Krystal Biotech Price Performance
NASDAQ:KRYS opened at $203.91 on Thursday. The business’s 50-day simple moving average is $193.15 and its 200-day simple moving average is $172.68. Krystal Biotech has a fifty-two week low of $93.95 and a fifty-two week high of $219.34. The stock has a market capitalization of $5.82 billion, a PE ratio of 109.04 and a beta of 0.84.
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.03. The company had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. During the same period in the previous year, the firm posted ($1.25) EPS. The business’s quarterly revenue was up 70283900.0% compared to the same quarter last year. On average, research analysts expect that Krystal Biotech will post 2 earnings per share for the current year.
About Krystal Biotech
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
- Five stocks we like better than Krystal Biotech
- Trading Stocks: RSI and Why it’s Useful
- BHP Stock: The Under-the-Radar Growth Story in Commodities
- Compound Interest and Why It Matters When Investing
- Analysts Upgrade These 3 Hot Buy-and-Hold Stocks
- Stock Sentiment Analysis: How it Works
- Kohl’s Charts a Resilient Path in a Challenging Retail Landscape
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.